IL-10-Producing CD4+ T Cells and Uses Thereof
AssigneesFondazione Telethon, Ospedale San Raffaele S.R.L., Fondazione Centro San Raffaele
InventorsSilvia Adriana GREGORI, Maria Grazia RONCAROLO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a CD4+ T cell that produces high levels of IL-10 for use in the treatment and/or prevention of a tumor that expresses CD13, HLA-class I and CD54 and/or for use in inducing Graft versus tumour (GvT). The present invention relates also to a composition comprising said cell and to a method to select a subject to be treated with said cell.
Claims14
(canceled)
2-26. (canceled)
A method of treating a human subject having a hematological cancer that expresses CD13, HLA-class I, and CD54, the method comprising:
- administering to the subject
- (a) allogeneic-hematopoietic stem cell transplant (allo-HSCT), and
- (b) human CD4+ T cells that have been genetically modified to comprise the coding sequence of human IL-10 under control of a constitutive promoter, wherein the genetically modified CD4+ T cells produce increased levels of human IL-10 compared to unmodified CD4+ T cells,
- wherein the genetically modified CD4+ T cells are not from the allo-HSCT donor and have not been anergized to subject (host) antigens in vitro, and
- wherein the genetically modified CD4+ T cells are administered in an amount sufficient to suppress the growth of the hematological cancer and to inhibit Graft vs Host Disease in the subject.
Dependencies are inferred from the claim text.